Late treatment with letrozole (Femara) can reduce breast cancer recurrence risk

[News]

Treatment with the aromatase inhibitor letrozole (Femara) can reduce the risk of breast cancer recurrence even when initiated one to seven years after a course of tamoxifen therapy.

More... (http://www.news-medical.net/?id=36100)